(CercleFinance.com) – Degroof Petercam announced on Tuesday that it has placed its price target on Poxel under review following the presentation of positive results from a phase II study in the treatment of NASH.
The financial intermediary – which considers this to be favorable data – recalls that this announcement was the most anticipated catalyst of the year.
However, he believes that it will be necessary to wait for the publication of the histological results, expected in September, to get a more precise idea of the mechanism of action of PXL065.
Degroof Petercam – which maintains a purchase recommendation on Poxel – however displays a certain caution on the file, recalling that the trials do not currently include any clinical criteria likely to justify a marketing authorization by the American FDA , such as reversal of NASH for 52 weeks without worsening of fibrosis.
Copyright © 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
